Sort
30,917 grants matching “tumor microenvironment”
Inhibition of angiogenesis by thrombospondin-1 (A2)
$348,364John W Lawler · Beth Israel Deaconess Medical Center · R01 · FY2011 · CA
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis
$348,363Liangfang Zhang · University Of California, San Diego · R01 · FY2019 · CA
Stimuli-responsive crosslinked theranostics against advanced prostate cancer
$348,363Yuanpei Li · University Of California At Davis · R01 · FY2019 · CA
RNAi screen of the glioblastoma stem cell kinome under hypoxia and normoxia
$348,305Brent H. Cochran · Tufts University Boston · R01 · FY2013 · NS
Role of the complement C3a receptor on immune and non immune intestinal barrier functions and microbiota in colorectal cancer development
$348,298Silvia Guglietta · Medical University Of South Carolina · R01 · FY2023 · CA
Role of Bone Marrow-Derived Myeloid Cells in Alcohol Liver Disease
$348,289Cynthia Ju · University Of Colorado Denver · U01 · FY2016 · AA
Counteracting molecular mechanisms of obesity dependent PDAC progression
$348,288Michael Nathan Vansaun · University Of Kansas Medical Center · R01 · FY2020 · CA
Counteracting molecular mechanisms of obesity dependent PDAC progression
$348,288Michael Nathan Vansaun · University Of Kansas Medical Center · R01 · FY2021 · CA
Mechanisms of Tumor Cell Dormancy and Tumor Recurrence
$348,284Jeffrey E Green · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy
$348,281Jessica E Thaxton · Medical University Of South Carolina · R01 · FY2020 · CA
Project 1: Arming Oncolytic HSV Vectors to Improve Virolysis in Syngeneic Mouse Models of GBM
$348,274Joseph C. Glorioso · Brigham And Women'S Hospital · P01 · FY2022 · CA
Lymph node-targeted molecular vaccines
$348,263Darrell J Irvine · Massachusetts Institute Of Technology · R01 · FY2018 · EB
The Role of CK2 in Glioblastoma Development
$348,244Etty N. Benveniste · University Of Alabama At Birmingham · R01 · FY2016 · CA
Improvement of cellular immunotherapy during dysbiosis- Resubmission
$348,182Ruud P.m. Dings · Univ Of Arkansas For Med Scis · R01 · FY2025 · CA
Core 1: Biospecimens Core
$348,162Jann N Sarkaria · Massachusetts Institute Of Technology · U54 · FY2023 · CA
Polyamine-based Therapy of Squamous Cell Carcinoma
$348,025Thomas G O'Brien · Lankenau Institute For Medical Research · R01 · FY2006 · CA
Vaccine-Dac/Bev Combinatorial Therapy in Ovarian Cancer
$348,000George Coukos · University Of Pennsylvania · R21 · FY2012 · CA
Vaccine-Dac/Bev Combinatorial Therapy in Ovarian Cancer
$348,000George Coukos · University Of Pennsylvania · R21 · FY2011 · CA
Photodynamic Therapy Affects on the Tumor Microenvironment
$347,975Charles Joseph Gomer · Children'S Hospital Of Los Angeles · R01 · FY2010 · CA
Macrophage-based ovarian cancer immunotherapy
$347,926Fiona E Yull · Vanderbilt University · R01 · FY2019 · CA
STINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBM
$347,923Amy Beth Heimberger · Northwestern University At Chicago · P50 · FY2025 · CA
Tissue-Engineered Models of Glioblastoma for Evaluating Treatment Response
$347,894Stephanie Kristin Seidlits · University Of Texas At Austin · R01 · FY2023 · CA
Obesity, inflammation and breast cancer
$347,787Weizhou Zhang · University Of Iowa · R01 · FY2018 · CA
Obesity, inflammation and breast cancer
$347,787Weizhou Zhang · University Of Iowa · R01 · FY2017 · CA
Biomimetic hydrogel niches to study the malignant phenotype of glioblastoma multiforme
$347,770Brendan A. Harley · University Of Illinois At Urbana-Champaign · R01 · FY2019 · CA